GAITHERSBURG, Md.--(BUSINESS WIRE)--Oct. 3, 2002--Gene Logic Inc., (Nasdaq:GLGC - News), announced today Fujisawa Pharmaceutical Co., Ltd., a global pharmaceutical company headquartered in Japan, has subscribed to Gene Logic's GeneExpress®Atlas DataSuite for use as a primary research tool in its drug discovery efforts.
Financial terms of the multi-year subscription agreement were not disclosed.
Under terms of the subscription agreement, Fujisawa's global researchers will gain use of the Atlas DataSuite and its related bioinformatics interface, the GeneExpress® Software System. The information obtained from the Atlas DataSuite will be used to support Fujisawa's internal target identification and target validation initiatives.
The Atlas DataSuite, a data subset of Gene Logic's BioExpress(TM) database, consists of comprehensive genomic and clinical information derived from a broad range of normal human tissues, tissues from model animal systems and human and animal cell lines.
The GeneExpress® Software System facilitates data mining, analysis, indexing and visualization of the Atlas DataSuite data. Fujisawa will receive periodic content and software updates, as well as ongoing training and customer support.
Commenting on the subscription agreement, David S. Murray, Senior Vice President for Marketing and Sales for Gene Logic said, "We are pleased to begin this subscription with Fujisawa Pharmaceutical and look forward to providing genomics-based solutions that enable and support their ongoing drug discovery and development initiatives."
Amersham Biosciences K.K., Gene Logic's sales and marketing partner in Japan, played a key role in facilitating Fujisawa's subscription to the GeneExpress® Atlas DataSuite.
"Our collaboration in Japan with Gene Logic has been very successful. As a leading provider of biotechnology systems, products and services for genomic research, Amersham Biosciences is enthusiastic about facilitating this and future collaborations between Japanese-based pharmaceutical companies and Gene Logic," stated Kazuo Takeuchi, Vice President at Amersham Biosciences K.K. in Tokyo. |
